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RESUMO – O melanoma maligno cutâneo é o terceiro tipo mais comum de cancro de pele, e a sua incidência tem aumentado. A 
taxa de mortalidade associada é considerável, devido ao seu fenótipo agressivo e grande capacidade de metastização, principal-
mente nos primeiros anos de seguimento. As recidivas tardias, mais de 10 anos após o diagnóstico, são raras. O principal fator 
de prognóstico do melanoma maligno cutâneo é a espessura tumoral, que também determina o tipo de abordagem. Os tumores 
finos, geralmente, têm bom prognóstico. Reportamos o caso de uma mulher de 66 anos com antecedentes de excisão de um me-
lanoma maligno cutâneo primário fino, localizado no dorso, que se apresentou 16 anos mais tarde com uma inesperada recidiva, 
rapidamente progressiva e letal.
PALAVRAS-CHAVE – Melanoma; Metastase Neoplásica; Neoplasias da Pele; Recidiva. 
Late Metastases from a Thin Primary Cutaneous 
Malignant Melanoma  
ABSTRACT – Cutaneous malignant melanoma is the third most common type of skin cancer, and its incidence has been rising. Its 
mortality rate is considerable, due to an aggressive phenotype and great ability of dissemination, mainly in the first years of follow-
-up. Late recurrences, those presenting more than 10 years after diagnosis, are rare. The main prognostic factor of cutaneous ma-
lignant melanoma is tumor thickness, which also guides management. Thin tumors often have a good prognosis. We report a case 
of a 66-year-old woman with a history of excision of a thin primary cutaneous malignant melanoma of the dorsum, presenting 16 
years later with an unexpected, rapidly progressing and lethal recurrence. 
KEYWORDS – Melanoma; Neoplasm Metastasis; Recurrence; Skin Neoplasms.
INTRODUCTION
Cutaneous malignant melanoma (CMM) is the third 
most common skin cancer, nevertheless its mortality rates 
are the highest among cutaneous neoplasms. Despite the 
increasing prevention campaigns, the incidences rates of 
CMM continue to raise in the majority of developed coun-
tries, especially in older people.1 Fortunately, the vast majo-
rity of cases are detected in an early stage, encouraging the 
concept of “cure” after adequate treatment. The aggressi-
veness of CMM is reflected in its capability to metastasize to 
locoregional or distant sites, particularly within first years of 
follow-up. Despite being an unusual event, late recurrence, 
defined as occurring more than 10 years after diagnosis, 
has been reported and is mainly characterized by distant 
disease.2-5
CASE REPORT
A 66-year-old woman was admitted in 2018 for a pro-
gressive cognitive decline and weight loss, in the last two 
months. Her family described signs of short-term memory 
loss and less autonomy in daily tasks. They also reported the 
synchronous development of nodular cutaneous lesions on 
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the trunk. The patient’s cancer screening tests were recent 
and normal. Her medical history was remarkable for a cuta-
neous malignant melanoma of the right scapular region, ma-
naged through wide excision at an oncology referral center, 
in 2002. Records of the primary tumor’s histopathological 
examination registered a superficial spreading melanoma, 
Clark level II, Breslow thickness of 1.00 mm, mitotic index 
of 3/mm2, without ulceration. The patient maintained annual 
surveillance, with no signs of recurrence up to the last follow-
-up visit, in 2017.
Physical examination revealed cognitive impairment on 
mental exam and a slight facial asymmetry, with no other 
motor or sensitive deficits. Multiple erythematous-purplish 
nodules ranging in size from one to 2 cm were palpable on 
the dorsum (Fig. 1A), scalp and arms, some of them with 
a dome-shaped form and a central crateriform ulceration. 
Erythematous-yellowish, firm, pearly papules, with a waxy 
surface were evident in the abdomen and breasts (Fig. 1B). 
Total-body skin examination did not reveal any suspicious pri-
mary cutaneous lesion.
Dermoscopy of papular lesions on the abdomen revea-
led dotted and linear irregular vessels, homogenously dis-
tributed over a pink-yellowish background without pigment 
network (Fig. 2). However, regarding the patient’s onco-
logic history and clinical presentation, these dermoscopic 
findings raised the possibility of a melanoma recurrence. A 
skin biopsy was performed, and the histologic examination 
showed a neoplasia with well-defined boundaries limited to 
the dermis (Fig. 3A), composed of proliferating atypical me-
lanocytes without melanic pigment (Fig. 3B); intraepidermal 
neoplastic component was not observed, which was compa-
tible with metastasis. The melanocytic origin was confirmed 
by the diffuse expression of MiTF (Fig. 3C) and Melan-A (Fig. 
3D). Imaging studies revealed carcinomatous-like ascites, 
thoracic adenopathies, cerebral hemorrhages and menin-
geal tumor dissemination.
The patient was proposed for palliative care. Neverthe-
less, her neurological status rapidly deteriorated and she 
died three days after confirmation of the diagnosis.
DISCUSSION
The estimated incidence of late recurrences of CMM 
is 0.5% - 3.5%, according to the published series.6 These 
cases have been explained by “tumor dormancy”, a period 
in cancer progression in which residual disease is present 
but remains asymptomatic. The mechanisms regulating 
this phenomenon are not fully understood, but they might 
rely on host and tumor factors, respectively immunosurvei-
llance, and cell cycle arrest or preferential hematogenous 
spread.7,8
One of the most important prognostic factors of CMM is 
tumor thickness.9,10 Our patient had been previously trea-
ted	 for	a	 thin	 (≤1.00	mm)	primary	 tumor,	without	ulcera-
tion. According to the 2002 American Joint Committee on 
Cancer (AJCC) staging criteria, the patient was classified as 
stage IA, and underwent wide excision without prior sen-
tinel lymph node biopsy (SLNB).11,12 Retrospectively, SLNB 
was not advocated as a standard of care for CMM pa-
tients.13 It was actually incorporated for the first time in the 
AJCC staging manual in its 6th edition (2002), which stated 
that CMM pathologic stage IA did not require pathologic 
Figure 1 - Erythematous nodules distributed over the dorsum and an 
ulcerated tumour lesion on the left shoulder (A); erythematous papules, 
with a waxy surface, in the right hypochondrium (B).
A
B
Figure 2 - Dermoscopy revealing dotted and linear irregular vessels, 
on a background with no pigment network (x10).
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evaluation of their lymph nodes.11 The role of SLNB apart 
from clinical trials was questioned, since no impact on sur-
vival had been proved, neither the effectiveness of adjuvant 
therapy (interferon alfa) had been established.13,14 The sub-
sequent approval of targeted therapies and immune check-
point inhibitors revolutionized the management of CMM, by 
demonstrating a survival advantage in the adjuvant setting 
of sentinel lymph node positive patients. Thus, SLNB is now 
recognized as a standard staging procedure, in appropria-
te cases.9,15 For thin tumors, however, the prognostic value 
of SLNB results is still unclear, making it difficult to predict 
those that might progress.16,17 There are some reports iden-
tifying possible predictive factors for late recurrences from 
thin primary tumors, namely ulceration, younger age and 
mitotic rate.8,18 The last two predictors were noteworthy in 
our case.
One could argue that, given the long interval between 
initial tumor and recurrence, the second disease represen-
ted a new malignancy. Since total-body skin examination 
of the patient showed no evidence of a new primary cuta-
neous cancer, metastases would have to originate from an 
unknown second primary tumor. Reported cases of distant 
disease from an unknown primary are even rarer than late 
recurrences, with an estimated rate of 0.2%.19 Nevertheless, 
this possibility could never be ruled out. 
Finally, cutaneous metastases of our patient presented 
no melanotic pigment, which may have been a confoun-
ding element. Nonetheless, the dermoscopic findings, 
specifically the vascular pattern of lesions, raised the possi-
bility of an amelanotic recurrence.20 Melanoma metastases 
can display features different from the primary tumor, at 
the morphologic and genetic level.7 Therefore, besides the 
particular attention to new pigmented lesions in the wide 
excision scar and surrounding skin, physicians must also 
be aware of amelanotic recurrences, in which dermoscopy 
might be a useful tool for the differential diagnosis.20
We herein report an unusual case of a CMM amelanotic 
recurrence, sixteen years after surgical resection of a thin 
primary tumor. This case highlights current recommenda-
tions about lifetime surveillance of CMM patients, including 
those with an expected good prognosis.9,10 New predictors 
and biomarkers are warranted to elucidate which patients 
with earlier stages might benefit from additional work-up or 
adjuvant therapy.
Presentations / Apresentações
This case has already been presented as an oral com-
munication in the XVIII National Congress of the Portuguese 
Society of Dermatology and Venereology (30th November - 
2nd December 2018, Lisbon, Portugal), and as a poster in 
the XXXVII Reunion Anual de Dermatologos Latinoamerica-
nos (4-7th May 2019, Buenos Aires, Argentina).
Figure 3 - Microphotograph showing a neoplasia composed of atypical melanocytes, exclusively located in the dermis (A, H&E x100), with abundant 
mitotic figures (B, H&E x400). Neoplastic cells positively stained for MiTF (C, x100) and Melan-A (D, x100).
A B
C D
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